Does tocilizumab eliminate inflammation in GCA? A cohort study on repeated temporal artery biopsies
Background Vascular inflammation persists in temporal artery biopsy (TAB) of giant cell arteritis (GCA) patients even after prolonged glucocorticoid (GC) therapy. We aimed to evaluate the histological impact of adding tocilizumab (TCZ) to GCs.Methods We enrolled all consecutive GCA patients with an...
Saved in:
Main Authors: | Chiara Marvisi, Francesco Muratore, Carlo Salvarani, Pierluigi Macchioni, Pamela Mancuso, Luigi Boiardi, Stefania Croci, Paolo Giorgi Rossi, Alberto Cavazza, Annibale Versari, Rexhep Durmo, Caterina Ricordi, Martina Bonacini, Giuseppe Malchiodi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-12-01
|
Series: | RMD Open |
Online Access: | https://rmdopen.bmj.com/content/10/4/e005132.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bing–Neel Syndrome: An Unknown GCA Mimicker
by: Arifa Javed, et al.
Published: (2024-01-01) -
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
by: Patrice Cacoub, et al.
Published: (2023-06-01) -
OMERACT GCA phantom project: validation of a 3D-printed ultrasound training phantom for diagnosis of giant cell arteritis
by: Annamaria Iagnocco, et al.
Published: (2025-02-01) -
Tension Recordings from Primary Bronchi in Acta2-GCaMP8.1-mVermilion Transgenic Mice
by: Qais Khalaf, et al.
Published: (2024-12-01) -
Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients
by: Yong Wang, et al.
Published: (2022-01-01)